Pfizer, Inc. · NYSE:PFE
Pfizer — Citi 2010 Global Healthcare Conference
8 slides from Pfizer's conference presentation, May 26, 2010
Slide 1: Pfizer Emerging Markets
Pfizer Emerging Markets Jean-Michel Halfon President and General Manager May 26, 2010
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are d
Slide 3: Six Markets Projected to Drive ~75% of EM Growth
Six Markets Projected to Drive ~75% of EM Growth Emerging markets industry • Current market size is nearly growth 2009–14 (US $ Billion) $200B ~140B ~60B • Priority markets expected to (43%) drive ~75% of total EM growth over next 4 years – China: 43% ~40B (29%) – Other 5 priority markets: 29% ~20B
Slide 4: Expected Key Growth Drivers for Pfizer Emerging Markets
Expected Key Growth Drivers for Pfizer Emerging Markets Priority Markets Top Products Contribution Contribution to to 2009–14 2009–14 revenue revenue growth growth 23% Others 62% BRICMT 15% AGMs China contributes 34% revenue growth Projected Average CAGR 2009-2014: 14% 4
Slide 5: Projected Acceleration of China Growth Organically and Via Business Development
Projected Acceleration of China Growth Organically and Via Business Development Projected Pfizer Growth Projected China Market Growth • Wyeth: vaccines ~$140 billion • Branded generics ~$100 billion + BD ~$40 billion 2017 Revenues Asia Strategy: geographic/field 2015 • China: ranked 2nd force expans
Slide 6: Prevenar 13: A Projected Growth Driver for Pfizer
Prevenar 13: A Projected Growth Driver for Pfizer Prevenar 13 Pediatric Prevenar 13 Adult • Builds on the scientific foundation and • Expected to become the first vaccine for proven experience of Prevenar adults and the standard of care for the long- term prevention of pneumococcal disease • Provide
Slide 7: Pricing Strategy Is Based on Local Market and Competitive Dynamics
Pricing Strategy Is Based on Local Market and Competitive Dynamics • Key considerations: – Disease areas – Socioeconomic – Market dynamics 55% average price – Viable margins differential between US – Tenders and tiered pricing – and emerging markets e.g. vaccines – Institutional buyers – e.g. rifabu
Slide 8: Q&A
Q&A